The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Realm Therapeutics

20 Feb 2019 10:33

RNS Number : 6181Q
Nplus1 Singer Capital Markets Ltd
20 February 2019
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Realm Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Realm Therapeutics Plc

(d) Date dealing undertaken:

19 February 2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 10p

 

 

Purchase

 

4,872,800

 

8p

 

6.5p

 

Ord 10p

 

 

Sale

 

4,540,124

 

7.989p

 

6.5p

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

20 February 2019

Contact name:

Damian Fernandez

Telephone number:

020 7496 3094

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERBGGDDBXDBGCG
Date   Source Headline
18th Aug 20167:00 amRNSBlock listing Interim Review
17th Aug 20167:00 amRNSPuriCore Receives Two U.S. Patents
16th Jun 201611:39 amRNSResult of AGM
9th Jun 20167:00 amRNSCompletion of Pre-IND Meeting with FDA on PR022
27th May 20167:00 amRNSResolution reached with EPA
14th Apr 20167:00 amRNSAppointment of Dr. Christian Peters as CMO
31st Mar 20167:00 amRNSNotice of AGM
29th Mar 20163:11 pmRNSDirector Dealing
29th Mar 20167:00 amRNSGrant of Options
24th Mar 20163:22 pmRNSAnnual Financial Report
24th Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSAppointment of Dr Simba Gill to the Board
19th Feb 20169:30 amRNSBlocklisting Interim Review
8th Feb 20167:00 amRNSStrategic Review and Trading Update
4th Jan 201610:21 amRNSHolding(s) in Company
21st Dec 20158:55 amRNSHolding(s) in Company
14th Oct 20155:13 pmRNSDirector Dealing
30th Sep 20156:08 pmRNSHolding(s) in Company
28th Sep 20157:00 amRNSDirector Dealings
23rd Sep 20157:00 amRNSHalf Yearly Report
19th Aug 20158:33 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSChange of Registered Office
19th Jun 20157:00 amRNSBoard Changes
18th Jun 201511:00 amRNSResult of AGM
9th Jun 20155:02 pmRNSGrant of Options
19th May 20157:00 amRNSAppointment of Alex Martin as CEO
2nd Apr 20157:00 amRNSDirector Dealing
31st Mar 20157:00 amRNSFinal Results
30th Mar 201512:22 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSSigns Major Supermarket Deal
24th Feb 20157:00 amRNSTrading Update
17th Feb 20158:24 amRNSBlocklisting Interim Review
9th Jan 20157:00 amRNSHolding(s) in Company
23rd Dec 20148:00 amRNSCancellation - PuriCore Plc
23rd Dec 20147:00 amRNSPuricore commences trading on AIM
25th Nov 20147:00 amRNSStrategic and Operational Review Update
24th Nov 20142:03 pmRNSResult of General Meeting
7th Nov 20147:00 amRNSProposed listing changes and notice of GM
5th Nov 20147:00 amRNSPuriCore granted two U.S. patents
31st Oct 20147:00 amRNSInterim Management Statement
14th Oct 20147:00 amRNSPlanned Directorate Changes
12th Aug 201411:49 amRNSDirector Dealing
11th Aug 20147:00 amRNSBlocklisting Interim Review
8th Aug 20147:00 amRNSHalf Yearly Report
31st Jul 20141:51 pmRNSNotice of Results
11th Jul 20147:00 amRNSTrading Update and Strategic Review
1st Jul 20147:00 amRNSCompletes Sale of UK Endoscopy Business
23rd Jun 20147:00 amRNSBoard Changes
20th Jun 201410:59 amRNSResult of General Meeting
19th Jun 201411:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.